Ligand Pharmaceuticals Incorporated (LGNXZ)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	67.67	72.31	22.95	45.01	19.52	47.62
Short-Term Investments	177.35	183.86	147.36	166.86	321.59	363.57
Cash & Short-Term Investments	245.02	256.17	170.31	211.87	341.11	411.19
Cash Growth	7.97%	50.41%	-19.62%	-37.89%	-17.04%	-61.57%
Accounts Receivable	51.56	38.38	32.92	30.42	85.45	56.85
Other Receivables	0.83	4.07	6.4	4.61	6.19	2.22
Receivables	52.39	42.45	39.31	35.04	91.65	59.06
Inventory	15.49	14.11	23.97	13.29	27.33	26.49
Prepaid Expenses	-	1.93	1.18	1.13	-	-
Restricted Cash	-	-	-	-	-	0.34
Other Current Assets	40.04	16.9	2.66	2.27	4.67	3.48
Total Current Assets	352.95	331.56	237.43	263.6	464.75	500.56
Property, Plant & Equipment	11.62	24.81	25.06	27.49	32.6	37.17
Long-Term Investments	10.91	10.91	49.32	3	-	-
Goodwill	101.54	105.25	103.37	105.67	105.67	189.66
Other Intangible Assets	250.13	266.65	299.61	352.64	386.8	606.31
Long-Term Accounts Receivable	193.56	185.02	62.29	-	-	-
Long-Term Deferred Tax Assets	0.83	0.07	0.21	8.53	35.73	24.32
Other Long-Term Assets	27.07	17.51	9.92	1.74	272.03	4.27
Total Assets	948.6	941.77	787.22	762.67	1,298	1,362
Accounts Payable	8.58	5.23	2.43	5.31	8.4	3.78
Accrued Expenses	15.09	25.53	10.09	13.3	12.4	15.61
Current Portion of Long-Term Debt	-	-	-	76.7	-	-
Current Portion of Leases	1.11	1.29	0.41	0.72	1.41	8.48
Current Income Taxes Payable	0.31	1.2	-	-	-	-
Current Unearned Revenue	0.11	1.28	1.22	0.36	0.65	29.44
Other Current Liabilities	39.53	2.58	2.63	2.43	18.8	42.8
Total Current Liabilities	64.73	37.11	16.78	98.81	41.67	100.11
Long-Term Debt	-	-	-	-	320.72	442.29
Long-Term Leases	4.63	5.86	5.77	10.34	2.31	5.76
Long-Term Unearned Revenue	-	18.18	15.14	0.04	-	-
Long-Term Deferred Tax Liabilities	32.25	32.52	31.62	30.62	30.86	64.6
Other Long-Term Liabilities	18.47	17.65	16.98	25.37	80.88	40
Total Liabilities	120.08	111.34	86.3	165.18	476.43	652.76
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	358.64	337.38	198.7	147.59	372.97	318.36
Retained Earnings	461.38	498.98	503.02	450.86	449.09	391.95
Comprehensive Income & Other	8.49	-5.94	-0.82	-0.98	-0.92	-0.8
Total Common Equity	828.53	830.44	700.91	597.49	821.16	709.53
Shareholders' Equity	828.53	830.44	700.91	597.49	821.16	709.53
Total Liabilities & Equity	948.6	941.77	787.22	762.67	1,298	1,362
Total Debt	5.74	7.15	6.18	87.75	324.44	456.53
Net Cash (Debt)	239.28	249.01	164.13	124.12	16.66	-45.34
Net Cash Growth	9.09%	51.72%	32.23%	644.83%	-	-
Net Cash Per Share	12.61	13.61	9.24	7.36	0.97	-2.69
Filing Date Shares Outstanding	19.6	19.26	17.71	17.08	16.85	16.61
Total Common Shares Outstanding	19.41	19.11	17.56	16.95	16.77	16.08
Working Capital	288.21	294.45	220.65	164.79	423.09	400.45
Book Value Per Share	42.68	43.46	39.92	35.25	48.97	44.13
Tangible Book Value	476.86	458.54	297.94	139.18	328.69	-86.45
Tangible Book Value Per Share	24.57	24.00	16.97	8.21	19.60	-5.38
Machinery	-	8.72	7.78	15.16	14.34	15.72
Construction In Progress	-	4.22	4.12	-	-	-
Leasehold Improvements	-	10.46	10.36	7.45	5.27	3.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.